Biotinidase biochemical and molecular analyses: Experience at a large reference laboratory

Rajesh Sharma,Cathlin R. Kucera,Camille R. Nery,Felicitas L. Lacbawan,Denise Salazar,Pranoot Tanpaiboon

DOI: https://doi.org/10.1111/ped.15726

2024-02-03

Pediatrics International

Abstract:Background Biotinidase deficiency is caused by absent activity of the biotinidase, encoded by the biotinidase gene (BTD). Affected individuals cannot recycle the biotin, leading to heterogeneous symptoms that are primarily neurological and cutaneous. Early treatment with biotin supplementation can prevent irreversible neurological damage and is recommended for patients with profound deficiency, defined as enzyme activity C, and 19/84 were novel BTD variants. A total of 36 patients had enzyme activity T. No variant was reported in one patient in the profound deficiency group. The most common variant found in patients with enzyme activity more than 10% MN was c.1330G>C. Conclusions Although enzyme activity alone may be adequate for diagnosing profound biotinidase deficiency, molecular testing is necessary for accurate carrier screening and in cases where the enzyme activity falls in the range where partial deficiency and carrier status cannot be discriminated.

pediatrics